Tiny study on drug monitoring in scleroderma ends early
NCT ID NCT04244916
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 30 times
Summary
This study aimed to find the best level of a drug called mycophenolate mofetil (MMF) in the blood to improve skin tightness and lung function in people with systemic sclerosis. Only 2 people joined before the study was stopped early. The research was designed to see if measuring drug levels could help doctors adjust doses for better results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cochin hospital, AP-HP
Paris, France, 75014, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.